Biotech Analyst Kluska and Biopharma Analyst Kim, along with Dr. Mehta of Allergy and Asthma Associates and Dr. Moss of University of Wisconsin Hospital, discuss Celldex Therapeutics data and Allakos’ Lirentelimab (Siglec-8 directed agonist) in Chronic Urticaria on an Analyst/Industry conference call to be held on February 26 at 12:45 pm. Webcast Link
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CLDX:
- Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
- Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
- Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023